FDA

#Biologics #Cell and gene therapy #Clinical research #Comment #FDA #Regulatory

The significance of FDA industry guidance on cell and gene therapies 

On 4 November 2022, the FDA’s Center for Biologics Evaluation and Research released guidance for the industry on studying multiple versions of a cellular or gene therapy (CGT) product in an early-phase clinical trial in a single disease1. This guidance finalises the draft guidance of the same title dated September… Read More

#Exclusive Content #Opinion #Regulatory

Patient with dry eye disease using eye drops
#Dry eye #FDA #Ophthalmology #Phase III trial #Stem cells

Stem cell dry eye therapy could offer rapid and total relief

The US Food and Drug Administration (FDA) has approved the Phase III clinical trial design for BRIM Biotechnology’s lead candidate for dry eye disease (DED), BRM421. BRIM will submit the Phase III study protocol to the FDA later this year.  BRM421 is a novel, first-in-class regenerative peptide therapy which, if… Read More

#News #Regulatory

Vaccination in pregnancy
#FDA #Pregnancy #Tdap #Whooping cough

First-ever Tdap vaccine approved by the FDA

Boostrix has become the first approved vaccine in the US to help protect infants younger than two months from pertussis (whooping cough).  The US Food and Drug Administration (FDA) has approved Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) for immunisation… Read More

#News

Ice Bucket Challenge
#ALS #Drug discovery #FDA #Fundraising #Ice Bucket Challenge #The ALS Association

‘Ice Bucket Challenge’ funds FDA-approved ALS treatment

The US Food and Drug Administration (FDA) has granted approval to AMX0035, a new treatment for people living with amyotrophic lateral sclerosis (ALS). Development of the drug was funded by $2.2 million from the ALS Association, raised by the 2014 social media craze the ‘Ice Bucket Challenge'. Another 40 potential… Read More

#News #Regulatory #Trending News

#Covid-19 #Drug approvals #FDA #Influenza #Rare disease

This week in drug discovery (19-23 September)

News round-up for 19-23 September by DDW Editor Reece Armstrong An interesting week for clinical research and drug approvals, with rare diseases being a key focus for both the FDA and European Commission. The last week has seen data emerge on how Omicron infection could protect against influenza, how… Read More

#News

Neurons
#FDA #Gene therapy #Neurodegenerative disorders

FDA approves gene therapy for rare neurological disorder

SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). The US Food and Drug Administration (FDA) has granted Accelerated Approval to bluebird bio’s SKYSONA (elivaldogene autotemcel), also known as eli-cel, in boys four to 17 years of age… Read More

#News #Regulatory

#Alzheimer's #Cancer research #Colorectal cancer #Drug discovery #Eczema #FDA #Plaque Psoriasis

This week in drug discovery (12-16 September)

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. … Read More

#News

Plaque Psoriasis
#Dermatology #FDA #Plaque Psoriasis #Psoriasis

FDA approves new first-line therapy for plaque psoriasis

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s allosteric tyrosine kinase 2 inhibitor Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. It is approved in patients who are candidates for systemic therapy or phototherapy, but not recommended in combination with other potent immunosuppressants. Read More

#News

Soft tissue sarcoma
#Cancer research #Chemotherapy #FDA #Orphan drugs

Soft tissue sarcoma drug receives FDA Orphan Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma.  AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology so that it is activated predominantly in… Read More

#Cancer Research #News

#Actigen #FDA #Rare disease #Regulatory

Actigen moves closer to clinical trial for rare disease treatment  

Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA).    The Cambridge-based biotech filed for a pre-IND advice meeting with the FDA to discuss the… Read More

#News

#FDA #Genetic diseases #Genetics #R&D

Sitting down with BridgeBio Pharma

Listen to this article on the DDW Podcast: Michael Henderson, MD, Chief Business Officer of BridgeBio Pharma, tells Lu Rahman about the company’s pursuit of transformative medicines to treat genetic diseases. BridgeBio’s mission is to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and… Read More

#Exclusive Content #Opinion

#FDA #Schizophrenia

FDA approves new drug for schizophrenia related agitation 

The Food and Drug Administration (FDA) has approved biopharmaceutical company BioXcel Therapeutics’ acute treatment for schizophrenia or bipolar disorder-associated agitation.   BioXcel Therapeutics’ IGALMI (dexmedetomidine) is the first new treatment for schizophrenia or bipolar disorder-associated agitation in almost 10 years, according to the company.  The FDA’s… Read More

#News

#Cancer #FDA #Pancreatic cancer

This week in DDW – oncology focus

DDW Deputy Editor Reece Armstrong takes a look at some of the biggest developments that took place within oncology this week (4 April – 8 April).  Scientists win award for transforming breast cancer treatment  A team of scientists from The Institute of Cancer Research, London,… Read More

#Cancer Research #News

#FDA #Immuno-oncology #Regulatory

Noxopharm granted ODD for lead oncology drug  

Australian biotech Noxopharm has received an Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for its lead oncology candidate in the treatment of soft tissue sarcoma.   Noxopharm’s Veyonda is a formulation of a first-in-class, dual-acting oncotoxic and immuno-oncology molecule known as idronoxil. Idronoxil is… Read More

#News

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna

Moderna receives full FDA approval for Covid-19 vaccine Spikevax 

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Moderna’s Spikevax, an mRNA vaccine for prevention of Covid-19 in individuals 18 years of age and older.  Official comments   “Our Covid-19 vaccine has been administered to hundreds of millions of… Read More

#News

#Covid booster #Covid-19 #FDA #Immunology / Virology & Vaccines #mRNA

Additional dose of Covid-19 vaccine is safe, says US trial 

A study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that an additional dose of a Covid-19 vaccine is safe in adults who had previously received a full regimen of any of three Covid-19 vaccines granted Emergency Use Authorization… Read More

#News #Trending News